ERBB2 and breast carcinoma: Afatinib, as an oral small molecule, irreversibly inhibits HER1, -2, and -4 receptors.125 A phase II study in trastuzumab-resistant metastatic patients showed partial response in patients with progressive HER2-positive breast cancer.126 The most frequent AEs related to Afatinib include diarrhea and rash.